Země: Spojené státy
Jazyk: angličtina
Zdroj: NLM (National Library of Medicine)
PRAVASTATIN SODIUM (UNII: 3M8608UQ61) (PRAVASTATIN - UNII:KXO2KT9N0G)
Blenheim Pharmacal, Inc.
PRAVASTATIN SODIUM
PRAVASTATIN SODIUM 10 mg
ORAL
PRESCRIPTION DRUG
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets USP are indicated to: - reduce the risk of myocardial infarction (MI). - reduce the risk of undergoing myocardial revascularization procedures. - reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. Pravastatin sodium tablets USP are indicated: - as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein chol
Pravastatin sodium tablets USP are supplied as: 10 mg tablets: Yellow colored, circular shaped tablets having flat surface, with “G5” debossed on one surface and “10” debossed on the other surface. They are supplied in bottles of 90 (NDC 68462-195-90) and bottles of 500 (NDC 68462-195-05). Bottles contain a desiccant canister. 20 mg tablets: Yellow rounded-rectangular tablets having biconvex surface, with “G5” debossed on one surface and “20” debossed on the other surface. They are supplied in bottles of 90 (NDC 68462-196-90) and bottles of 500 (NDC 68462-196-05). Bottles contain a desiccant canister. 40 mg tablets: Green rounded-rectangular tablets having biconvex surface, with “G5” debossed on one surface and “40” debossed on the other surface. They are supplied in bottles of 90 (NDC 68462-197-90) and bottles of 500 (NDC 68462-197-05). Bottles contain a desiccant canister. 80 mg tablets: Yellow oval tablets having biconvex surface, with “G5” debossed on one surface and “80” debossed on the other surface. They are supplied in bottles of 90 (NDC 68462-198-90) and bottles of 500 (NDC 68462-198-05). Bottles contain a desiccant canister. Store at 20 o to 25 o C (68 o to 77 o F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.
Abbreviated New Drug Application
PRAVASTATIN SODIUM- PRAVASTATIN SODIUM TABLET BLENHEIM PHARMACAL, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PRAVASTATIN SODIUM TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PRAVASTATIN SODIUM TABLETS. PRAVASTATIN SODIUM TABLETS USP, FOR ORAL USE INITIAL U.S. APPROVAL: 1991 INDICATIONS AND USAGE Pravastatin sodium tablets USP are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2) Limitations of use: Pravastatin sodium tablets USP have not been studied in _Fredrickson _Types I and V dyslipidemias. ( 1.3) DOSAGE AND ADMINISTRATION Adults: the recommended starting dose is 40 mg once daily. Use 80 mg dose only for patients not reaching LDL-C goal with 40 mg. ( 2.2) Significant renal impairment: the recommended starting dose is 10 mg once daily. ( 2.2) Children (ages 8 to 13 years, inclusive): the recommended starting dose is 20 mg once daily. ( 2.3) Adolescents (ages 14 to 18 years): the recommended starting dose is 40 mg once daily. ( 2.3) DOSAGE FORMS AND STRENGTHS Tablets: 10 mg, 20 mg, 40 mg, 80 mg. ( 3) CONTRAINDICATIONS Hypersensitivity to any component of this medication. ( 4.1, 6.2, 11) Active liver disease or unexplained, persistent elevations of serum transaminases. ( 4.2, 5.2) Women who are pregnant or may become pregnant. ( 4.3, 8.1) Nursing mothers. ( 4.4 Přečtěte si celý dokument